Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00156013 · ClinicalTrials.gov registry record · Phase 1
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
A Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, B-Cell, sponsored by Oncology Specialists, S.C..
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT00156013 is a Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, B-Cell that has completed, run by Oncology Specialists, S.C.. The registered enrollment target is 33 participants, below the 394-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00156013, a Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, B-Cell, has completed, sponsored by Oncology Specialists, S.C..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to develop new treatment for non-hodgkin's lymphoma in subjects whose cancer has returned or resisted treatment with chemotherapy. The investigational drug clofarabine is being used in this study. An investigational drug is one that has not been approved by the United States Food and Drug Administration (FDA).
Conditions Studied
Interventions
- DRUG CLOFARABINE
Study Locations (1)
Illinois
- Oncology Specialists, SC - Park Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2005-09 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00156013
The ClinicalTrials.gov registry entry for NCT00156013 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 394-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (92% lower). The listed sponsor is Oncology Specialists, S.C., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which CLOFARABINE is the first listed.
NCT00156013 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00156013 about?
NCT00156013 is a clinical study titled "Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)". This research is being done to develop new treatment for non-hodgkin's lymphoma in subjects whose cancer has returned or resisted treatment with chemotherapy. The investigational drug clofarabine is being used in this study. An investigational drug is one that has not been approved by the United Sta...
What is the current status of trial NCT00156013?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2005-09. Estimated completion is 2010-04.
What conditions does trial NCT00156013 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell.
What interventions are being tested in trial NCT00156013?
The interventions under investigation include: CLOFARABINE (DRUG).
Who is sponsoring clinical trial NCT00156013?
This trial is sponsored by Oncology Specialists, S.C., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00156013 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.